The document summarizes the UWCCC/WON Molecular Tumor Board (MTB) and Registration Protocol. The MTB is a panel of experts that provides treatment recommendations based on pathology or genomics analysis. Physicians can submit cases for review to receive recommendations for clinical trials, off-label drugs, or standard treatment. The Registration Protocol collects genomic, clinical, and outcome data to evaluate the effectiveness of targeted therapies recommended by the MTB.
The document discusses the WONIX initiative which aims to provide Wisconsin residents access to advanced molecular imaging clinical trials. It outlines WONIX's objectives to increase availability of imaging agents, improve imaging standards, establish data sharing, create a data warehouse, and conduct state-of-the-art clinical studies. A key focus is reducing uncertainties in quantitative PET imaging through harmonization of patient preparation, injection methods, scanning parameters, image processing and analysis across sites. The presentation describes WONIX's site training and qualification process which uses phantoms to ensure high image quality and calibrated scanners. Harmonizing reconstruction parameters across scanners can significantly reduce SUV value differences for patients scanned on different machines.
Patient handling equipment is an assistive devices allowing the hospitalized patients to transfer to other places who lack the strength to control the body movements. Patient handling equipment’s are specially designed in helping the patients in hospitals, nursing homes and medical centers with some mobility. The equipment’s are cost efficient than retrofitting, assures increased productivity of care givers and ensures patient’s safety.
The document describes a new Virtual Lesion Clinic (VLC) service in Waikato, New Zealand that aims to improve access to dermatology services and reduce waiting times. The VLC uses teledermatology where skin lesions are photographed, sent digitally to dermatologists for diagnosis, and treatment plans are developed without requiring an in-person visit. An analysis found the VLC reduced waiting times by 67% compared to traditional clinics and lowered costs by 20% while maintaining good patient satisfaction. Plans are to expand the VLC model to other regions with limited dermatologist access.
Victorian HIV Service STI Project: How simple is to ordering a blood test? Presentation given by Brian Price at the AFAO National Syphilis Forum, 23 October 2009.
The Cancer Imaging Archive (TCIA) is a service which de-identifies and hosts a large archive of medical images of cancer accessible for public download.
- Update on new data sets
- New features
- New publications
- Other news
Universal access to virtual colonoscopy may be on the horizonYael Waknine
Virtual colonoscopy (CT colonography) has been endorsed by several medical organizations since 2008 as a screening method for colorectal cancer. However, it is not covered by Medicare for reimbursement due to political opposition from organizations supporting traditional colonoscopy and concerns about risks. Radiologists argue that many of the original concerns about virtual colonoscopy have been addressed by peer-reviewed research showing it is a safe and cost-effective screening option. They call for public advocacy to change the test's rating by the US Preventive Services Task Force in order to gain Medicare coverage, which would significantly boost low colorectal cancer screening rates in the US.
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions.
The webinar was followed by an interactive question & answer session.
The document summarizes the UWCCC/WON Molecular Tumor Board (MTB) and Registration Protocol. The MTB is a panel of experts that provides treatment recommendations based on pathology or genomics analysis. Physicians can submit cases for review to receive recommendations for clinical trials, off-label drugs, or standard treatment. The Registration Protocol collects genomic, clinical, and outcome data to evaluate the effectiveness of targeted therapies recommended by the MTB.
The document discusses the WONIX initiative which aims to provide Wisconsin residents access to advanced molecular imaging clinical trials. It outlines WONIX's objectives to increase availability of imaging agents, improve imaging standards, establish data sharing, create a data warehouse, and conduct state-of-the-art clinical studies. A key focus is reducing uncertainties in quantitative PET imaging through harmonization of patient preparation, injection methods, scanning parameters, image processing and analysis across sites. The presentation describes WONIX's site training and qualification process which uses phantoms to ensure high image quality and calibrated scanners. Harmonizing reconstruction parameters across scanners can significantly reduce SUV value differences for patients scanned on different machines.
Patient handling equipment is an assistive devices allowing the hospitalized patients to transfer to other places who lack the strength to control the body movements. Patient handling equipment’s are specially designed in helping the patients in hospitals, nursing homes and medical centers with some mobility. The equipment’s are cost efficient than retrofitting, assures increased productivity of care givers and ensures patient’s safety.
The document describes a new Virtual Lesion Clinic (VLC) service in Waikato, New Zealand that aims to improve access to dermatology services and reduce waiting times. The VLC uses teledermatology where skin lesions are photographed, sent digitally to dermatologists for diagnosis, and treatment plans are developed without requiring an in-person visit. An analysis found the VLC reduced waiting times by 67% compared to traditional clinics and lowered costs by 20% while maintaining good patient satisfaction. Plans are to expand the VLC model to other regions with limited dermatologist access.
Victorian HIV Service STI Project: How simple is to ordering a blood test? Presentation given by Brian Price at the AFAO National Syphilis Forum, 23 October 2009.
The Cancer Imaging Archive (TCIA) is a service which de-identifies and hosts a large archive of medical images of cancer accessible for public download.
- Update on new data sets
- New features
- New publications
- Other news
Universal access to virtual colonoscopy may be on the horizonYael Waknine
Virtual colonoscopy (CT colonography) has been endorsed by several medical organizations since 2008 as a screening method for colorectal cancer. However, it is not covered by Medicare for reimbursement due to political opposition from organizations supporting traditional colonoscopy and concerns about risks. Radiologists argue that many of the original concerns about virtual colonoscopy have been addressed by peer-reviewed research showing it is a safe and cost-effective screening option. They call for public advocacy to change the test's rating by the US Preventive Services Task Force in order to gain Medicare coverage, which would significantly boost low colorectal cancer screening rates in the US.
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions.
The webinar was followed by an interactive question & answer session.
Krisann L Lorentz Welter is a detail-oriented, ARRT certified radiographer with experience in diagnostic imaging, computed tomography, and bone densitometry. She recently graduated from Northern Michigan University's Radiography Program with an Associate of Applied Science degree. Her clinical experience includes working at Munising Memorial Hospital and UP Health Systems Marquette where she gained experience in various radiographic procedures and modalities. She is certified in CPR and is a member of several radiology professional organizations.
CancerLinQ aims to harness big data to improve cancer care by learning from every patient. It faces challenges of integrating diverse data types from genomics to behaviors. Its goals are precision, personalized medicine through molecular profiling of individual cancers. As clinical trials enroll few patients, CancerLinQ would provide real-world data from electronic health records to uncover new insights. When deployed, it will analyze de-identified patient records to uncover care patterns, allow comparing care to guidelines and peers, and provide evidence-based guidance. This has the potential to improve outcomes for patients and quality for providers and researchers.
SITIST 2015 Dev - Turning big data into presicion medicine real life examplessitist
Big data in healthcare comes from a variety of sources and formats including clinical trials, patient records, medical literature, genomic data, and medical imaging. This large volume of data presents challenges to make it accessible and usable. SAP offers platforms and solutions to unlock the value in healthcare big data by enabling precision medicine through analyzing diverse clinical and genomic data sources. Examples include SAP's partnership with ASCO on the CancerLinQ project to link oncology data and improve cancer treatment, and SAP Medical Research Insights deployed at the National Center for Tumor Diseases in Heidelberg, Germany.
Avastin in Breast Cancer Powered by InCrowd June 2011Kathleen Poulos
The document discusses a June 2011 FDA hearing on the approval status of Avastin for metastatic breast cancer. It summarizes the drug's approval history and failed confirmatory studies. It also shares the results of a survey of oncologists by InCrowd prior to the hearing, finding they were nearly evenly split on whether the Avastin indication should be maintained or removed, and on whether the hearing should be open or closed to the public.
1. The document discusses factors that should be incorporated into models to predict therapy-induced toxicities following radical prostatectomy, such as surgeon experience and surgical technique.
2. It addresses predicting urinary incontinence and erectile dysfunction following surgery and touches on morbidity profiles.
3. The need for standardized reporting of surgical complications using criteria such as the Martin criteria is discussed, as well as designing next generation predictive models in urology.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
Nicole Walker is a radiologic technologist with over 15 years of experience in medical imaging. She has advanced certifications in CT and mammography. Currently she works as a CT technologist where she performs various CT procedures and utilizes her experience in patient safety. Previously she has worked in mammography and as a family support coordinator for a cancer center. She is seeking to utilize her skills and certifications in radiology.
This document provides an overview of clinical trial accrual challenges and discusses how social media could potentially help address some of these challenges. It summarizes the National Clinical Trials Network (NCTN) and reviews major accrual barriers experienced by institutions, investigators, and patients. These include a lack of trial awareness, preference for standard care over trials, and concerns about side effects. The document then describes NCI's use of Twitter to promote NCTN trials and poses questions about how social media could enhance awareness of cancer clinical trials.
Innovative Care in Urology: Collaborative and High TechAllina Health
This document summarizes innovative care in urology at Virginia Piper Cancer Institute through collaboration between urology, oncology, pathology, radiology, and genetics departments. Over 350 patients have been presented at monthly conferences since 2011, with 20 enrolled in clinical trials. Integration with other departments provides cancer support groups, preoperative classes, and social services. Robotic surgery in urology has led to decreased lengths of stay for prostatectomy by 30%, partial nephrectomy by 21%, and cystectomy by 12%. A review of 84 small renal mass cases treated with active surveillance, robotic partial nephrectomy, or CT guided cryotherapy showed a 95% success rate at 2 year follow up.
This document compares the comparative effectiveness research (CER) and relative effectiveness (RE) evidence environments in the US and Europe. It identifies critical factors and likely scenarios for each region by 2020. Both regions will see increasing demands for CER/RE evidence from payers to demonstrate value. The US will make greater progress in data and analytics capabilities while Europe increases harmonization between regulators and health technology assessors. Adaptive licensing will be implemented in Europe but not the US.
Shelby Hassberger Comeaux is a senior consultant at the CDC with over 10 years of experience in public health surveillance. She has led projects involving disease surveillance systems, health data standards, and emergency response. She is currently pursuing a Master's degree in biomedical science.
Taylor Smith's career write-up discusses radiology. Radiologic technologists produce x-rays of the body to diagnose medical issues. They position patients and equipment, take x-rays, and develop films. Technologists work in hospitals and doctors' offices, standing for long periods. Training ranges from 1-4 years and leads to certification, which most employers require. Employment is expected to grow 15% by 2016 with an aging population needing more imaging. Median pay was $48,170 in 2006.
Clinical Trial Results Transparency and the Changing Paradigm of Medical Comm...ClinTrialsClick
This document discusses how clinical trial transparency requirements are challenging the traditional model of medical communications. It outlines how regulations have evolved over time to require registration and public reporting of clinical trial results. Two examples are given showing how earlier disclosure of trial results on platforms like ClinicalTrials.gov impacted the traditional publication process. The document argues that empowering end users to access and understand complex clinical trial data requires making results more findable, navigable and understandable beyond current formats. It proposes a model of a "Gout Resource Center" to centrally organize gout trial results in a standardized, searchable format with user-friendly tools.
Caris Life Sciences provides comprehensive molecular profiling services to help guide cancer treatment decisions. They have a large laboratory campus in Arizona that offers multiple technology platforms to analyze tumor biology. Caris also has a network of cancer centers that collaborate to profile patients, track outcomes, publish research, and establish guidelines for integrating molecular testing into care. The goal is to illuminate treatment options and match patients to therapies or clinical trials through their molecular intelligence reports.
Telemedicine at the Minnesota State FairSamantha Haas
The Great Plains Telehealth Resource & Assistance Center provided telemedicine screenings at the Minnesota State Fair, where over 1.5 million people attend annually. Over 500 fairgoers were screened using teledermatology and pulmonary function testing, with over 30% referred for further evaluation. Physicians conducted nearly 600 screenings over 18 telemedicine sessions, averaging 27 screenings per hour. The telehealth demonstrations provided an important public service by screening for diseases and encouraging medical follow-up, while also educating about telehealth benefits. A patient later thanked the program for detecting and removing a cancerous mole that saved their life.
The document outlines a marketing campaign to raise awareness about colorectal cancer screening. The objectives are to spread awareness about colorectal bleeding and cancer screening and generate brand recall for screening. Key points of the campaign include having doctors discuss the importance of screening on air, promoting cancer screening and free screening at a hospital through radio advertisements and mentions. The campaign aims to increase footfall for screening and detection to help prevent and cure cancers.
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
Cross-border genetic testing is widespread, particularly for rare diseases, with over 18,000 samples crossing borders in 2002. Samples are sent abroad for tests not available locally, centralization of testing, or lower costs. However, this creates issues around quality assurance, finding high-quality labs, reimbursement policies, and data protection. Initiatives like the Genetics Quality Assurance database aim to help address these issues by providing information on lab accreditation and participation in proficiency testing.
Utilization of virtual microscopy in a cooperative group settingBIT002
The document discusses the use of virtual microscopy in cooperative cancer research groups. It summarizes the Research Informatics Core's role in developing digital pathology solutions to improve review times and access for cooperative groups like the Children's Oncology Group. Key applications discussed include the Virtual Imaging for Pathology, Education and Research (VIPER) system and efforts to integrate virtual microscopy with gene expression data through the Virtual Microscopy to Microarray (VM2M) project. Future goals include incorporating additional data types and developing more sophisticated analysis and search capabilities.
MseqDR consortium: a grass-roots effort to establish a global resource aimed ...Human Variome Project
The success of whole exome sequencing (WES) for highly heterogeneous disorders, such as mitochondrial disease, is limited by substantial technical and bioinformatics challenges to correctly identify and prioritize the extensive number of sequence variants present in each patient. The likelihood of success can be greatly improved if a large cohort of patient data is assembled in which sequence variants can be systematically analysed, annotated, and interpreted relative to known phenotype. This effort has engaged and united more than 100 international mitochondrial clinicians, researchers, and bioinformaticians in the Mitochondrial Disease Sequence Data Resource (MSeqDR) consortium that formed in June 2012 to identify and prioritize the specific WES data analysis needs of the global mitochondrial disease community. Through regular web-based meetings, we have familiarized ourselves with existing strengths and gaps facing integration of MSeqDR with public resources, as well as the major practical, technical, and ethical challenges that must be overcome to create a sustainable data resource. We have now moved forward toward our common goal by establishing a central data resource (http://mseqdr.org/) that has both public access and secure web-based features that allow the coherent compilation, organization, annotation, and analysis of WES and mtDNA genome data sets generated in both clinical- and research-based settings of suspected mitochondrial disease patients. The most important aims of the MSeqDR consortium are summarized in the MSeqDR portal within the Consortium overview sections. Consortium participants are organized in 3 working groups that include (1) Technology and Bioinformatics; (2) Phenotyping, databasing, IRB concerns and access; and (3) Mitochondrial DNA specific concerns. The online MSeqDR resource is organized into discrete sections to facilitate data deposition and common reannotation, data visualization, data set mining, and access management. With the support of the United Mitochondrial Disease Foundation (UMDF) and the NINDS/NICHD U54 supported North American Mitochondrial Disease Consortium (NAMDC), the MSeqDR prototype has been built. Current major components include common data upload and reannotation using a novel HBCR based annotation tool that has also been made publicly available through the website, MSeqDR GBrowse that allows ready visualization of all public and MSeqDR specific data including labspecific aggregate data visualization tracks, MSeqDR-LSDB instance of nearly 1250 mitochondrial disease and mitochodnrial localized genes that is based on the Locus Specific Database model, exome data set mining in individuals or families using the GEM.app tool, and Account & Access Management. Within MSeqDR GBrowse it is now possible to explore data derived from MitoMap, HmtDB, ClinVar, UCSC-NumtS, ENCODE, 1000 genomes, and many other resources that bioinformaticians recruited to the project are organizing.
Krisann L Lorentz Welter is a detail-oriented, ARRT certified radiographer with experience in diagnostic imaging, computed tomography, and bone densitometry. She recently graduated from Northern Michigan University's Radiography Program with an Associate of Applied Science degree. Her clinical experience includes working at Munising Memorial Hospital and UP Health Systems Marquette where she gained experience in various radiographic procedures and modalities. She is certified in CPR and is a member of several radiology professional organizations.
CancerLinQ aims to harness big data to improve cancer care by learning from every patient. It faces challenges of integrating diverse data types from genomics to behaviors. Its goals are precision, personalized medicine through molecular profiling of individual cancers. As clinical trials enroll few patients, CancerLinQ would provide real-world data from electronic health records to uncover new insights. When deployed, it will analyze de-identified patient records to uncover care patterns, allow comparing care to guidelines and peers, and provide evidence-based guidance. This has the potential to improve outcomes for patients and quality for providers and researchers.
SITIST 2015 Dev - Turning big data into presicion medicine real life examplessitist
Big data in healthcare comes from a variety of sources and formats including clinical trials, patient records, medical literature, genomic data, and medical imaging. This large volume of data presents challenges to make it accessible and usable. SAP offers platforms and solutions to unlock the value in healthcare big data by enabling precision medicine through analyzing diverse clinical and genomic data sources. Examples include SAP's partnership with ASCO on the CancerLinQ project to link oncology data and improve cancer treatment, and SAP Medical Research Insights deployed at the National Center for Tumor Diseases in Heidelberg, Germany.
Avastin in Breast Cancer Powered by InCrowd June 2011Kathleen Poulos
The document discusses a June 2011 FDA hearing on the approval status of Avastin for metastatic breast cancer. It summarizes the drug's approval history and failed confirmatory studies. It also shares the results of a survey of oncologists by InCrowd prior to the hearing, finding they were nearly evenly split on whether the Avastin indication should be maintained or removed, and on whether the hearing should be open or closed to the public.
1. The document discusses factors that should be incorporated into models to predict therapy-induced toxicities following radical prostatectomy, such as surgeon experience and surgical technique.
2. It addresses predicting urinary incontinence and erectile dysfunction following surgery and touches on morbidity profiles.
3. The need for standardized reporting of surgical complications using criteria such as the Martin criteria is discussed, as well as designing next generation predictive models in urology.
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
Presentation by Michael Seewald, Michael Seewald, Ph.D.
Global Head Evidence, AstraZeneca Biopharmaceuticals for mHealth Israel, October 19th, 2021.
Real-World Data is able to uncover local unmet medical need – Call to action to build Learning Healthcare Systems. Significant Variations in Care and Large Potential for Improvement. Real-World Data helps to benchmark efficient use of resources and detect “waste”. Healthcare systems need to address the problem of waste. But fundamental change is hard, and progress slow. Outcomes Transparency Improves ComplianceExample: Swedish myocardial infarction registry. Outcomes Transparency Improves Compliance. Example: Swedish myocardial infarction registry. Improving Outcomes and Creating Value will continue to guide Learning Healthcare Systems- enabled by RWD. Four technological trends as accelerators on our path. Empowered patients- Molecular screening and 24/7 monitoring driving a step change in diagnosis. Algorithmic decision-making: Artificial intelligence supports physician intelligence. Evidence-generating healthcare systemsLive insights on clinical efficacy from digital monitoring. 360° care delivery. Home replaces hospital via digital therapeutics and on-demand remote support. AstraZeneca Areas of Partnering Interest: (https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html).
Nicole Walker is a radiologic technologist with over 15 years of experience in medical imaging. She has advanced certifications in CT and mammography. Currently she works as a CT technologist where she performs various CT procedures and utilizes her experience in patient safety. Previously she has worked in mammography and as a family support coordinator for a cancer center. She is seeking to utilize her skills and certifications in radiology.
This document provides an overview of clinical trial accrual challenges and discusses how social media could potentially help address some of these challenges. It summarizes the National Clinical Trials Network (NCTN) and reviews major accrual barriers experienced by institutions, investigators, and patients. These include a lack of trial awareness, preference for standard care over trials, and concerns about side effects. The document then describes NCI's use of Twitter to promote NCTN trials and poses questions about how social media could enhance awareness of cancer clinical trials.
Innovative Care in Urology: Collaborative and High TechAllina Health
This document summarizes innovative care in urology at Virginia Piper Cancer Institute through collaboration between urology, oncology, pathology, radiology, and genetics departments. Over 350 patients have been presented at monthly conferences since 2011, with 20 enrolled in clinical trials. Integration with other departments provides cancer support groups, preoperative classes, and social services. Robotic surgery in urology has led to decreased lengths of stay for prostatectomy by 30%, partial nephrectomy by 21%, and cystectomy by 12%. A review of 84 small renal mass cases treated with active surveillance, robotic partial nephrectomy, or CT guided cryotherapy showed a 95% success rate at 2 year follow up.
This document compares the comparative effectiveness research (CER) and relative effectiveness (RE) evidence environments in the US and Europe. It identifies critical factors and likely scenarios for each region by 2020. Both regions will see increasing demands for CER/RE evidence from payers to demonstrate value. The US will make greater progress in data and analytics capabilities while Europe increases harmonization between regulators and health technology assessors. Adaptive licensing will be implemented in Europe but not the US.
Shelby Hassberger Comeaux is a senior consultant at the CDC with over 10 years of experience in public health surveillance. She has led projects involving disease surveillance systems, health data standards, and emergency response. She is currently pursuing a Master's degree in biomedical science.
Taylor Smith's career write-up discusses radiology. Radiologic technologists produce x-rays of the body to diagnose medical issues. They position patients and equipment, take x-rays, and develop films. Technologists work in hospitals and doctors' offices, standing for long periods. Training ranges from 1-4 years and leads to certification, which most employers require. Employment is expected to grow 15% by 2016 with an aging population needing more imaging. Median pay was $48,170 in 2006.
Clinical Trial Results Transparency and the Changing Paradigm of Medical Comm...ClinTrialsClick
This document discusses how clinical trial transparency requirements are challenging the traditional model of medical communications. It outlines how regulations have evolved over time to require registration and public reporting of clinical trial results. Two examples are given showing how earlier disclosure of trial results on platforms like ClinicalTrials.gov impacted the traditional publication process. The document argues that empowering end users to access and understand complex clinical trial data requires making results more findable, navigable and understandable beyond current formats. It proposes a model of a "Gout Resource Center" to centrally organize gout trial results in a standardized, searchable format with user-friendly tools.
Caris Life Sciences provides comprehensive molecular profiling services to help guide cancer treatment decisions. They have a large laboratory campus in Arizona that offers multiple technology platforms to analyze tumor biology. Caris also has a network of cancer centers that collaborate to profile patients, track outcomes, publish research, and establish guidelines for integrating molecular testing into care. The goal is to illuminate treatment options and match patients to therapies or clinical trials through their molecular intelligence reports.
Telemedicine at the Minnesota State FairSamantha Haas
The Great Plains Telehealth Resource & Assistance Center provided telemedicine screenings at the Minnesota State Fair, where over 1.5 million people attend annually. Over 500 fairgoers were screened using teledermatology and pulmonary function testing, with over 30% referred for further evaluation. Physicians conducted nearly 600 screenings over 18 telemedicine sessions, averaging 27 screenings per hour. The telehealth demonstrations provided an important public service by screening for diseases and encouraging medical follow-up, while also educating about telehealth benefits. A patient later thanked the program for detecting and removing a cancerous mole that saved their life.
The document outlines a marketing campaign to raise awareness about colorectal cancer screening. The objectives are to spread awareness about colorectal bleeding and cancer screening and generate brand recall for screening. Key points of the campaign include having doctors discuss the importance of screening on air, promoting cancer screening and free screening at a hospital through radio advertisements and mentions. The campaign aims to increase footfall for screening and detection to help prevent and cure cancers.
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
Cross-border genetic testing is widespread, particularly for rare diseases, with over 18,000 samples crossing borders in 2002. Samples are sent abroad for tests not available locally, centralization of testing, or lower costs. However, this creates issues around quality assurance, finding high-quality labs, reimbursement policies, and data protection. Initiatives like the Genetics Quality Assurance database aim to help address these issues by providing information on lab accreditation and participation in proficiency testing.
Utilization of virtual microscopy in a cooperative group settingBIT002
The document discusses the use of virtual microscopy in cooperative cancer research groups. It summarizes the Research Informatics Core's role in developing digital pathology solutions to improve review times and access for cooperative groups like the Children's Oncology Group. Key applications discussed include the Virtual Imaging for Pathology, Education and Research (VIPER) system and efforts to integrate virtual microscopy with gene expression data through the Virtual Microscopy to Microarray (VM2M) project. Future goals include incorporating additional data types and developing more sophisticated analysis and search capabilities.
MseqDR consortium: a grass-roots effort to establish a global resource aimed ...Human Variome Project
The success of whole exome sequencing (WES) for highly heterogeneous disorders, such as mitochondrial disease, is limited by substantial technical and bioinformatics challenges to correctly identify and prioritize the extensive number of sequence variants present in each patient. The likelihood of success can be greatly improved if a large cohort of patient data is assembled in which sequence variants can be systematically analysed, annotated, and interpreted relative to known phenotype. This effort has engaged and united more than 100 international mitochondrial clinicians, researchers, and bioinformaticians in the Mitochondrial Disease Sequence Data Resource (MSeqDR) consortium that formed in June 2012 to identify and prioritize the specific WES data analysis needs of the global mitochondrial disease community. Through regular web-based meetings, we have familiarized ourselves with existing strengths and gaps facing integration of MSeqDR with public resources, as well as the major practical, technical, and ethical challenges that must be overcome to create a sustainable data resource. We have now moved forward toward our common goal by establishing a central data resource (http://mseqdr.org/) that has both public access and secure web-based features that allow the coherent compilation, organization, annotation, and analysis of WES and mtDNA genome data sets generated in both clinical- and research-based settings of suspected mitochondrial disease patients. The most important aims of the MSeqDR consortium are summarized in the MSeqDR portal within the Consortium overview sections. Consortium participants are organized in 3 working groups that include (1) Technology and Bioinformatics; (2) Phenotyping, databasing, IRB concerns and access; and (3) Mitochondrial DNA specific concerns. The online MSeqDR resource is organized into discrete sections to facilitate data deposition and common reannotation, data visualization, data set mining, and access management. With the support of the United Mitochondrial Disease Foundation (UMDF) and the NINDS/NICHD U54 supported North American Mitochondrial Disease Consortium (NAMDC), the MSeqDR prototype has been built. Current major components include common data upload and reannotation using a novel HBCR based annotation tool that has also been made publicly available through the website, MSeqDR GBrowse that allows ready visualization of all public and MSeqDR specific data including labspecific aggregate data visualization tracks, MSeqDR-LSDB instance of nearly 1250 mitochondrial disease and mitochodnrial localized genes that is based on the Locus Specific Database model, exome data set mining in individuals or families using the GEM.app tool, and Account & Access Management. Within MSeqDR GBrowse it is now possible to explore data derived from MitoMap, HmtDB, ClinVar, UCSC-NumtS, ENCODE, 1000 genomes, and many other resources that bioinformaticians recruited to the project are organizing.
Generation and Use of Quantitative Pathology PhenotypeJoel Saltz
Motivation, tools and methods analysis of digital pathology imagery, integration with "omics" and Radiology, use in Precision Medicine. Presentation at the Early Detection Research Network meeting, April 2015, Atlanta GA
PanCareSurPass @SIOP Europe/CCI Europe Meeting 2021, Riccardo HauptKylieOBrien10
Research Manager Dr. Riccardo Haupt presented the PanCareSurPass project at the ‘PanCare and ELTEC – Late effects’ session of the SIOP Europe/CCI Europe Meeting 2021 on 28th April 2021.
PanCareSurPass has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 89999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
A surgical council was formed with members from different hospitals within a health system to establish a single standard of surgical care across all hospitals. The council used the ACS NSQIP program to measure surgical outcomes and identify areas for improvement. Initial efforts focused on educating surgeons and staff about NSQIP reporting. Process improvement projects addressed local needs identified in the NSQIP data. Collaboration with other departments led to standardization of resources to improve quality and reduce costs. As a result, problem areas were addressed, practices and equipment were standardized, and an electronic health record was implemented across the system. The matured surgical council continues working on a larger scale to share initiatives and lessons learned to achieve best practices system-wide.
The document provides information about the SPIE Medical Imaging conference to be held February 15-20, 2014 in San Diego, California. It calls for submissions of abstracts by August 12, 2013 on topics related to medical imaging technologies and their biomedical applications. The conference will cover all aspects of medical imaging including physics, image processing, computer-aided diagnosis, image-guided procedures, and various imaging modalities. Authors are encouraged to present their latest research on imaging physics, systems, applications, and image analysis.
Univ of Miami CTSI: Citizen science seminar; Oct 2014Richard Bookman
The University of Miami's Clinical & Translational Science Institute runs a seminar course for MS students.
This talk surveys 8 citizen science projects, reviews NIH's current activities, and identifies issues for attention, particularly with ethical, legal and social implications.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
This document summarizes the NIH Roadmap for Medical Research presented by Jeremy M. Berg of the National Institute of General Medical Sciences on April 30, 2004. It outlines the challenges facing NIH, including rapid changes in science, increasing complexity of research, and convergence of disciplines. The Roadmap aims to accelerate discoveries, translate research more rapidly to patients, and develop novel strategies through initiatives like New Pathways to Discovery, Re-engineering the Clinical Research Enterprise, and Research Teams of the Future. Key elements discussed include the development of molecular libraries, building biological pathways and networks, advances in structural biology including a new centers program, bioinformatics and computational biology national centers, and the nanomedicine initiative.
The InSiGHT-Human Variome Project Collaboration - Finlay MacraeHuman Variome Project
The International Society for Gastrointestinal Hereditary Tumours and the Human Variome Project have had a long and fruitful collaboration. Finlay Macrae, InSiGHT's Secretary spoke at the 4th Biennial Meeting of the Human Variome Project Consortium to update delegates on the progress of the collaboration and to share some of the methods that InSiGHT has used to build their organisation and their database.
This document summarizes a flexible analytical platform for precision clinical research, pharmaceutical R&D, and education. It describes the large and growing omics data analysis market and the need to extract biological meaning from big biomedical data. The platform uses machine learning, biological pathway analysis, visualization, and other techniques to analyze genomics, proteomics, transcriptomics, metabolomics, and other omics data types. It provides basic processing, predictive modeling, and decision support to help with clinical trials, molecular diagnostics, and more. The business model involves remote cloud access, full-service projects, reporting, customization, and educational programs. Testimonials highlight how the platform has helped diverse research teams.
Keynote at NVIDIA GPU Technology Conference in D.C.Jerry Lee
Presentation at NVIDIA GPU Technology Conference in D.C. on how the Cancer Moonshot Task Force under Vice President Biden is using AI to help end cancer as we know it. Dr. Lee will discuss global efforts to empower A.I. and deep learning for oncology with larger and more accessible datasets.
This document describes the development of an annotated bibliography of key population research and programming work in Kenya. It aims to enhance evidence-based policies for key populations (MSM, sex workers, people who inject drugs) by providing easy access to research. The bibliography was developed through a literature review that identified 98 peer-reviewed articles and 16 reports on key population research and programming in Kenya. An online platform was created to host the searchable bibliography and allow users to share information, moderate discussions, and upload additional content. The annotated bibliography seeks to regularly update policymakers, researchers and managers on evidence to help formulate relevant questions, policies and programs.
Real-World Evidence: The Future of Data Generation and UsageApril Bright
As data is captured through electronic health records, registries and unique device identifiers, the generation of evidence based on this data is expected to play a crucial role in informing orthopedic manufacturers’ decisions before and after regulatory approval. While regulators, payors, hospitals and manufacturers support this shift, they acknowledge that gaps remain in its optimal execution. Priority considerations include how to generate evidence to expedite regulatory market decisions, device indication expansion, postmarket studies, postmarket surveillance and reimbursement decisions. The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), is leading the conversation with various stakeholders, including FDA and orthopedic device companies to support the sustainable generation of Real-World Evidence (RWE) using Real-World Data (RWD).
Brad Doebbeling Slides for AHRQ Kick-Off EventShawnHoke
This document provides an overview of a project aimed at improving the integration of clinical decision support (CDS) into outpatient clinical workflow for colorectal cancer screening. The project will identify best practices for CDS integration across four health systems, develop and test redesigned CDS alternatives through simulation, and implement and evaluate the redesigned CDS in primary care clinics. The goal is to create CDS designs that improve efficiency, usability and reduce workload for providers.
The Human Variome Database in Australia in 2014 - Graham TaylorHuman Variome Project
There are a number of genetics and genomics initiatives underway in Australia, including the Australian node of the Human Variome Project (HVPA), as well as many active research collaborations including familial cancer, endocrine disease, and developmental delay. Most of these projects work with disease-specific databases on a research basis, with the risk that such archives may be ephemeral. HVPA is the only database that is directly integrated with accredited clinical reporting of variants. As such it is designed to capture variants that have passed scrutiny as diagnostically robust, and have therefore already been curated by qualified staff. Registered users access the HVPA database via a secure Internet portal.
I will describe three recent developments of the HVPA database and portal: the upgraded search interface, linkage to other datasets via BioGrid using hash-based de-identified case matching, and the introduction of a genome wide database using LOVD3. Finally I will discuss the future direction of the HVPA and the questions of utility, quality control and sustainability of genetic variation databases.
Search interface
The search interface has to provide useful tools for clinicians and lab scientists so that the HPVA project offers them direct benefits and incentivises them to participate. Following a request for feedback from users, a series of improvements were implemented, initially on a demonstration server and then on the live server following review by the Steering Committee. The highest priorities were for more information about numbers of times particular variants were
recorded, the ability to search by range and to filter by pathogenicity. There was also interest in enabling direct uploading of VCF files and the automated calculation of pathogenicity scores. Many of these features are now implemented and examples will be presented.
Linkage to other datasets
We have implemented the hash key algorithm and work is in progress with BioGrid to link variation data to clinical data sets.
Genome wide database
We have established an HVPA LOVD3 database and are working with the Human Genetics Society of Australasia on a pilot study to sequence the exomes of two trios and review the data using this database.
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
Similar to WONIX - Wisconsin Oncology Network of Imagine Excellence (20)
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
WONIX - Wisconsin Oncology Network of Imagine Excellence
1. Robert Jeraj
Associate Professor of Medical Physics, Human Oncology,
Radiology and Biomedical Engineering
Director of Wisconsin Oncology Network of Imaging eXcellence
University of Wisconsin Carbone Cancer Center, Madison, WI
2. Wisconsin Oncology Network
Aspirus Regional Cancer Center, Wausau
Aurora Cancer Care
Aurora HealthCare Network
Bellin Memorial Hospital, Green Bay
Columbia-St. Mary’s, Milwaukee
Dean Clinic Heme/Onc
Ferguson Cancer Center, Freeport, IL
Fox Valley Heme/Onc
Gundersen Lutheran, La Crosse
Holy Family Cancer Center, Manitowoc
Marshfield Clinic
Medical College of Wisconsin, Milwaukee
Mercy Health System, Janesville
ProHealth Care, Waukesha and Oconomowoc
St. Vincent Hospital, Green Bay
SwedishAmerican Hospital/SAH Regional
Cancer Center, Rockford, IL
UWCCC
UWCCC Partners, Johnson Creek, Wisconsin
Rapids
Vucurevich Cancer Center, Rapid City, SD
5. Molecular Imaging Agents
Working Group
To develop molecular imaging agents and make them
available to the WONIX sites. It includes development
of necessary distribution infrastructure and necessary
regulatory documentation for obtaining Investigator
New Drug (IND) approvals.
Chairs:
– Scott Perlman, Co-Chair
– Rebecca Marnocha, Co-Chair
Members: John Centanni, Scott Knishka, Yongjun
Yan, Todd Barnhart, Robert Jeraj, Anne Traynor,
Dona Alberti
6. Imaging quality assurance
Working Group
To establish “harmonized” imaging quality
assurance program across the WONIX sites.
Chairs:
– Chihwa Song, Co-Chair
– Matt La Fontaine, Co-chair
Members: Robert Pyzalski, Karl Vigen, Frank
Ranallo, Frank Korosec, Sean Fain, Guanghong
Chen, Ed Jackson, Robert Jeraj, Nagesh Adluru,
Chris Jaskowiak, Cheryl Gain
7. Informatics Working Group
To enable automated workflows, data collection
and integration, and processes that enable scalable
clinical trials within WONIX
Chairs:
– Richard Bruce, Co-chair
– Sean Fain, Co-Chair
Members: Gary Wendt, Andy Craven, Chihwa
Song, Matt La Fontaine, Cheryl Gain, Jonathon
Boott
8. Data Working Group
To develop common database platform and
appropriate tools for data analysis and data mining
Chairs:
– Umberto Tachinardi (Co-chair)
– Jonathan Boott (Co-chair)
Members: Stephine Wasielewski, Mary Jane
Staab, Jill Kolesar, Richard Bruce, Robert Jeraj,
Dona Alberti
9. Imaging clinical trials
Working Group
To design, coordinate and execute individual
imaging clinical trial projects through the WONIX
network.
Chairs:
– Robert Jeraj, Co-Chair
– Glenn Liu, Co-chair
Members: George Wilding, Anne Traynor, Ryan
Mattison, Kari Wisinski, Scott Perlman,
Jill Kolesar, Dona Alberti, Jennifer Heideman
10. Clinical trials
Retrospective analysis of FDG PET/CT in NSCLC
– Current UW pilot (20 pts) will be extended (200 pts)
through WONIX
MITOS: FDG PET/CT in NSCLC
– Comprehensive genomic analysis and CTCs
– Early and late FDG PET/CT response assessment
– Piloted (3 pts) at UWCCC; WONIX amendments
– Soon to be activated through WONIX
NaF PET/CT in mCRPC
FDG PET/CT in lymphoma
FLT PET/CT in AML
…
11. Next steps
WONIX working groups:
– Molecular imaging agents: cGMP facility (Q1 2015)
– Imaging QA: Automated QA/QC monitoring (Q3 2015)
– Informatics: XDS data exchange platform (Q2 2015)
– Data: Common databased established (Q3 2015)
WONIX site activation (Q4 2014/Q1 2015)
– Gundersen, La Crosse (Q4 2014)
– St. Vincent, Green Bay (Q1 2015)
– Others to follow
WONIX clinical trial activation (Q1/Q2 2015)
– Retrospective FDG PET/CT analysis (Q1 2015)
– MITOS trial (Q2 2015)
– Others to follow